Patent · US Active

Binding agents to pre-fusion state SARS-CoV-2 spike protein

US11421019B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Inventors

Yang Xiang · Taiyuan, CN
Yan Tan · Beijing, CN

Key dates

Filing date	Sep 17, 2020
Grant date	Aug 23, 2022
Priority date	—
Expiry date	Dec 21, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/26
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.